|
|
|
Volumn 358, Issue 11, 2008, Pages 1196-
|
|
Cetuximab for colorectal cancer [5]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CETUXIMAB;
EPIDERMAL GROWTH FACTOR RECEPTOR;
ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
CANCER PATIENT;
COLORECTAL CANCER;
DISEASE MARKER;
HUMAN;
IMMUNOHISTOCHEMISTRY;
IMMUNOREACTIVITY;
LETTER;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
THERAPY EFFECT;
TREATMENT OUTCOME;
TREATMENT RESPONSE;
COLORECTAL TUMOR;
DISEASE FREE SURVIVAL;
IMMUNOLOGY;
KAPLAN MEIER METHOD;
NOTE;
PROPORTIONAL HAZARDS MODEL;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
COLORECTAL NEOPLASMS;
DISEASE-FREE SURVIVAL;
HUMANS;
KAPLAN-MEIERS ESTIMATE;
PROPORTIONAL HAZARDS MODELS;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
|
|
EID: 40849124008
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: None Document Type: Letter |
|
Times cited : (2)
|
|
References (0)
|
